{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:54Z","timestamp":1787067474033,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["107519"],"award-info":[{"award-number":["107519"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["128107"],"award-info":[{"award-number":["128107"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43TW010131"],"award-info":[{"award-number":["D43TW010131"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112579","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T06:46:48Z","timestamp":1640846808000},"page":"112579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies"],"prefix":"10.1016","volume":"146","author":[{"given":"Siphamandla R.","family":"Ngcobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongani B.","family":"Nkambule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda M.","family":"Nyambuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabelo","family":"Mokgalaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviwe","family":"Ntsethe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuyolwethu","family":"Mxinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanyisani","family":"Ziqubu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonela","family":"Ntamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thembeka A.","family":"Nyawo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phiwayinkosi V.","family":"Dludla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.112579_bib1","unstructured":"World Health Organization (WHO), Definition and Diagnosis Of Diabetes Mellitus And Intermediate Hyperglycemia. Available at: \u3008https:\/\/www.who.int\/diabetes\/publications\/Definition%20and%20diagnosis%20of%20diabetes_new.pdf\u3009. (Accessed 06 July 2021)."},{"key":"10.1016\/j.biopha.2021.112579_bib2","unstructured":"International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth Edition 2021. Available at: \u3008https:\/\/diabetesatlas.org\/\u3009. (Accessed 18 December 2021)."},{"issue":"24","key":"10.1016\/j.biopha.2021.112579_bib3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus \u2013 mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2021.112579_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9419413","article-title":"Peripheral arterial disease and its associated factors among type 2 diabetes mellitus patients at Debre Tabor General Hospital, Northwest Ethiopia","volume":"2020","author":"Akalu","year":"2020","journal-title":"J. Diabetes Res."},{"issue":"11 Suppl. 1","key":"10.1016\/j.biopha.2021.112579_bib5","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1210\/jc.2008-1595","article-title":"Obesity and the metabolic syndrome in developing countries","volume":"93","author":"Misra","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4093\/dmj.2016.40.4.272","article-title":"Roles of reactive oxygen species on insulin resistance in adipose tissue","volume":"40","author":"Han","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.biopha.2021.112579_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial","volume":"6","author":"Held","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.biopha.2021.112579_bib8","article-title":"IL-17 cytokines in immunity and inflammation","volume":"2","author":"Jin","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.biopha.2021.112579_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2019.100015","article-title":"Obesity-induced inflammation and insulin resistance: a mini-review on T-cells","volume":"3","author":"Nyambuya","year":"2019","journal-title":"Metab. Open"},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib10","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"10","key":"10.1016\/j.biopha.2021.112579_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2015.0095","article-title":"Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies","volume":"13","author":"Manna","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.biopha.2021.112579_bib12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1155\/2010\/289645","article-title":"Chronic inflammation in obesity and the metabolic syndrome","volume":"2010","author":"Monteiro","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2021.112579_bib13","doi-asserted-by":"crossref","first-page":"13436","DOI":"10.1038\/ncomms13436","article-title":"The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis","volume":"7","author":"Geng","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2021.112579_bib14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jth.12177","article-title":"The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review","volume":"11","author":"Anandasundaram","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/138920007780362590","article-title":"Chronic immune activation underlies morbid obesity: is IDO a key player?","volume":"8","author":"Brandacher","year":"2007","journal-title":"Curr. Drug Metab."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jth.12472","article-title":"Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation","volume":"12","author":"Capra","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2174\/15701611113116660175","article-title":"Inflammation, oxidative stress and metabolic syndrome: dietary modulation","volume":"11","author":"Fern\u00e1ndez-Garc\u00eda","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2021.112579_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2021.112579_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110550","article-title":"Immune defence to invasive fungal infections: a comprehensive review","volume":"130","author":"Pathakumari","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1901348","article-title":"Hyperglycemic memory of innate immune cells promotes in vitro proinflammatory responses of human monocytes and murine macrophages","volume":"206","author":"Thiem","year":"2021","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.15420\/ecr.2018.11.1","article-title":"Role of anti-inflammatory interventions in coronary artery disease: understanding the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"13","author":"Lorenzatti","year":"2018","journal-title":"Eur. Cardiol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12950-021-00292-6","article-title":"Therapeutic potential of a novel semi-synthetic-sulfated-polysaccharide to suppress inflammatory mediators in P. gingivalis LPS stimulated human monocytes\/macrophages","volume":"18","author":"Gu","year":"2021","journal-title":"J. Inflamm."},{"key":"10.1016\/j.biopha.2021.112579_bib25","doi-asserted-by":"crossref","first-page":"867023","DOI":"10.1155\/2012\/867023","article-title":"Altered polarization, morphology, and impaired innate immunity germane to resident peritoneal macrophages in mice with long-term type 2 diabetes","volume":"2012","author":"Liu","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.biopha.2021.112579_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.154999","article-title":"Elevated T-helper 2 cytokine levels in high fat diet-fed C57BL\/6 mice are attenuated by short-term 6-week treatment with a combination of low-dose aspirin and metformin","volume":"128","author":"Mahlangu","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2021.112579_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/nu11112695","article-title":"Impaired glucose tolerance is associated with enhanced platelet-monocyte aggregation in short-term high-fat diet-fed mice","volume":"11","author":"Mkandla","year":"2019","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib28","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2021.112579_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155360","article-title":"Short-term effect of non-surgical periodontal treatment on local and systemic cytokine levels: role of hyperglycemia","volume":"138","author":"Rabelo","year":"2021","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.biopha.2021.112579_bib30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.jhh.1001447","article-title":"Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus","volume":"16","author":"Nomura","year":"2002","journal-title":"J. Hum. Hypertens."},{"issue":"12","key":"10.1016\/j.biopha.2021.112579_bib31","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.bbadis.2013.08.006","article-title":"Endothelial dysfunction \u2013 a major mediator of diabetic vascular disease","volume":"1832","author":"Sena","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2021.112579_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/biology10030217","article-title":"Diet-induced obesity promotes the upregulation of Fas expression on T-cells","volume":"10","author":"Nyambuya","year":"2021","journal-title":"Biology"},{"issue":"44","key":"10.1016\/j.biopha.2021.112579_bib33","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.2174\/1381612825666190102104642","article-title":"Monocyte as an emerging tool for targeted drug delivery: a review","volume":"24","author":"Sabir","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"29","key":"10.1016\/j.biopha.2021.112579_bib34","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.2174\/1381612825666190830153056","article-title":"Macrophage: a key therapeutic target in atherosclerosis?","volume":"25","author":"Taghizadeh","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2021.112579_bib35","article-title":"Monocyte transmodulation: the next novel therapeutic approach in overcoming ischemic stroke?","volume":"11","author":"Park","year":"2020","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coph.2008.12.017","article-title":"The monocyte\/macrophage as a therapeutic target in atherosclerosis","volume":"9","author":"Saha","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41569-019-0265-3","article-title":"Transcriptional and epigenetic regulation of macrophages in atherosclerosis","volume":"17","author":"Kuznetsova","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2021.112579_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2020.100047","article-title":"Differential expression of glycoprotein IV on monocyte subsets following high-fat diet feeding and the impact of short-term low-dose aspirin treatment","volume":"7","author":"Mokgalaboni","year":"2020","journal-title":"Metab. Open"},{"key":"10.1016\/j.biopha.2021.112579_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104313","article-title":"The aberrant expression of CD69 on peripheral T-helper cells in diet-induced inflammation is ameliorated by low-dose aspirin and metformin treatment","volume":"363","author":"Nyambuya","year":"2021","journal-title":"Cell Immunol."},{"key":"10.1016\/j.biopha.2021.112579_bib40","article-title":"Monocyte-mediated inflammation and cardiovascular risk factors in type 2 diabetes mellitus: a systematic review and meta-analysis of pre-clinical and clinical studies","volume":"9","author":"Mokgalaboni","year":"2020","journal-title":"JRSM Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2021.112579_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154892","article-title":"A systematic review on the functional role of Th1\/Th2 cytokines in type 2 diabetes and related metabolic complications","volume":"126","author":"Mahlangu","year":"2020","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.biopha.2021.112579_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib44","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40259-016-0201-6","article-title":"Biosimilars for the treatment of chronic inflammatory diseases: a systematic review of published evidence","volume":"30","author":"Jacobs","year":"2016","journal-title":"BioDrugs"},{"issue":"17","key":"10.1016\/j.biopha.2021.112579_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4239\/wjd.v7.i17.354","article-title":"Update on the treatment of type 2 diabetes mellitus","volume":"7","author":"Mar\u00edn-Pe\u00f1alver","year":"2016","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.biopha.2021.112579_bib46","first-page":"1","article-title":"Diabetes: from research to clinical practice","volume":"1307","author":"Islam","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biopha.2021.112579_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.arr.2018.10.003","article-title":"Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing","volume":"48","author":"Prattichizzo","year":"2018","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11883-013-0314-z","article-title":"Metformin therapy in diabetes: the role of cardioprotection","volume":"15","author":"El Messaoudi","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.biopha.2021.112579_bib50","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12933-019-0860-y","article-title":"Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management","volume":"18","author":"Luo","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"25","key":"10.1016\/j.biopha.2021.112579_bib52","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehx668","article-title":"Cardioprotective anti-hyperglycaemic medications: a review of clinical trials","volume":"39","author":"Ahmed","year":"2018","journal-title":"Eur. Heart J."},{"issue":"Suupl. 2","key":"10.1016\/j.biopha.2021.112579_bib53","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1177\/2047487319880040","article-title":"Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases","volume":"26","author":"Prattichizzo","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(21)00245-X","article-title":"Glycaemic management in diabetes: old and new approaches","volume":"10","author":"Ceriello","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00592-008-0058-3","article-title":"Pioglitazone reduces monocyte activation in type 2 diabetes","volume":"46","author":"Pitocco","year":"2009","journal-title":"Acta Diabetol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib56","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2337\/diabetes.55.03.06.db05-0832","article-title":"The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment","volume":"55","author":"Marfella","year":"2006","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib57","doi-asserted-by":"crossref","first-page":"E606","DOI":"10.1210\/jc.2010-1858","article-title":"The effect of very-low-calorie diet on mRNA expression of inflammation-related genes in subcutaneous adipose tissue and peripheral monocytes of obese patients with type 2 diabetes mellitus","volume":"96","author":"Mraz","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2021.112579_bib58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.metabol.2004.11.017","article-title":"Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty","volume":"54","author":"Wang","year":"2005","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.biopha.2021.112579_bib59","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1210\/jc.2012-1544","article-title":"Sitagliptin exerts an antinflammatory action","volume":"97","author":"Makdissi","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib60","first-page":"150","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2021.112579_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1476-511X-9-144","article-title":"Treatment of dyslipidemia in patients with type 2 diabetes","volume":"9","author":"Vijayaraghavan","year":"2010","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jamacardio.2016.4320","article-title":"Statins and the prevention of heart disease","volume":"2","author":"Ziaeian","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12944-021-01586-7","article-title":"Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia","volume":"20","author":"Sivkov","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.biopha.2021.112579_bib64","article-title":"Statins and inflammation in cardiovascular disease","author":"Vogiatzi","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib65","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.fjc.0000175455.46245.c8","article-title":"Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates","volume":"46","author":"Okopie\u0144","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112579_bib66","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2006-0299","article-title":"Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome","volume":"91","author":"Devaraj","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib67","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000088948","article-title":"Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes\/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes","volume":"76","author":"Ichida","year":"2006","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2008.03.057","article-title":"Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome","volume":"102","author":"Singh","year":"2008","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.metabol.2014.10.011","article-title":"Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls","volume":"64","author":"de Vries","year":"2015","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2004.01.027","article-title":"Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes","volume":"174","author":"Nomura","year":"2004","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ecl.2013.09.005","article-title":"Type 2 diabetes mellitus and hypertension: an update","volume":"43","author":"Lastra","year":"2014","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/dom.14234","article-title":"Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes","volume":"23","author":"Inzucchi","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","article-title":"High blood pressure and cardiovascular disease","volume":"75","author":"Fuchs","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2021.112579_bib74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ahj.2020.09.017","article-title":"Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: the QUARTET randomized controlled trial protocol","volume":"231","author":"Chow","year":"2021","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1734-1140(10)70249-8","article-title":"Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances","volume":"62","author":"Krysiak","year":"2010","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.thromres.2005.04.008","article-title":"Effect of valsartan on monocyte\/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus","volume":"117","author":"Nomura","year":"2006","journal-title":"Thromb. Res."},{"key":"10.1016\/j.biopha.2021.112579_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117854","article-title":"The impact of metformin and aspirin on T-cell mediated inflammation: a systematic review of in vitro and in vivo findings","volume":"255","author":"Nyambuya","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2021.112579_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu11010023","article-title":"Inflammation and oxidative stress in an obese state and the protective effects of gallic acid","volume":"11","author":"Dludla","year":"2018","journal-title":"Nutrients"},{"issue":"24","key":"10.1016\/j.biopha.2021.112579_bib79","doi-asserted-by":"crossref","first-page":"12235","DOI":"10.1039\/D1FO02696H","article-title":"Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence","volume":"12","author":"Mokgalaboni","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.biopha.2021.112579_bib80","article-title":"Inflammatory activities in type 2 diabetes patients with co-morbid angiopathies and exploring beneficial interventions: a systematic review","volume":"8","author":"Nwadiugwu","year":"2020","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib81","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacl.2018.03.083","article-title":"Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: insights from metabolic biomarker profiling and network analysis","volume":"12","author":"Adiels","year":"2018","journal-title":"J. Clin. Lipidol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112579_bib82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2362.2004.01362.x","article-title":"Selenium supplementation decreases nuclear factor-kappa B activity in peripheral blood mononuclear cells from type 2 diabetic patients","volume":"34","author":"Faure","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.biopha.2021.112579_bib83","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s00125-012-2685-z","article-title":"N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial","volume":"55","author":"Treweeke","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2021.112579_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jsbmb.2017.09.011","article-title":"Vitamin D(3) supplementation decreases a unique circulating monocyte cholesterol pool in patients with type 2 diabetes","volume":"177","author":"Riek","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.atherosclerosis.2005.09.006","article-title":"Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages","volume":"187","author":"Rosenblat","year":"2006","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib86","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ilar.47.3.186","article-title":"Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition","volume":"47","author":"Cefalu","year":"2006","journal-title":"ILAR J."},{"issue":"3","key":"10.1016\/j.biopha.2021.112579_bib87","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.ATV.21.3.365","article-title":"Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice","volume":"21","author":"Collins","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2021.112579_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143396","article-title":"Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice","volume":"10","author":"Terasaki","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2021.112579_bib89","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2337\/db17-0744","article-title":"A novel strategy to prevent advanced atherosclerosis and lower blood glucose in a mouse model of metabolic syndrome","volume":"67","author":"Kanter","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2021.112579_bib90","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/972761","article-title":"Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome","volume":"2014","author":"Di Filippo","year":"2014","journal-title":"Mediat. Inflamm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112579_bib91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.atherosclerosis.2005.02.024","article-title":"Development of atherosclerosis in the diabetic BALB\/c mice. Prevention with Vitamin E administration","volume":"182","author":"Otero","year":"2005","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.biopha.2021.112579_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020301","article-title":"EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes","volume":"6","author":"Lim","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2021.112579_bib93","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3945\/jn.111.152322","article-title":"Genistein prevents hyperglycemia-induced monocyte adhesion to human aortic endothelial cells through preservation of the cAMP signaling pathway and ameliorates vascular inflammation in obese diabetic mice","volume":"142","author":"Babu","year":"2012","journal-title":"J. Nutr."},{"issue":"9","key":"10.1016\/j.biopha.2021.112579_bib94","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2337\/db17-0194","article-title":"The histone methyltransferase MLL1 directs macrophage-mediated inflammation in wound healing and is altered in a murine model of obesity and type 2 diabetes","volume":"66","author":"Kimball","year":"2017","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.biopha.2021.112579_bib95","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.imbio.2015.06.016","article-title":"TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes","volume":"220","author":"Lu","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.biopha.2021.112579_bib96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fcvm.2020.00022","article-title":"Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease","volume":"7","author":"Chait","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.biopha.2021.112579_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: from pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2021.112579_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112224","article-title":"The pleotropic effects of fluvastatin on complement-mediated T-cell activation in hypercholesterolemia","volume":"143","author":"Nyambuya","year":"2021","journal-title":"Biomed. Pharmacother."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221013664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:42:39Z","timestamp":1779964959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221013664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":98,"alternative-id":["S0753332221013664"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112579","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activated monocytes as a therapeutic target to attenuate vascular inflammation and lower cardiovascular disease-risk in patients with type 2 diabetes: A systematic review of preclinical and clinical studies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112579"}}